UK markets closed
  • FTSE 100

    5,737.49
    -54.52 (-0.94%)
     
  • FTSE 250

    17,611.59
    -241.71 (-1.35%)
     
  • AIM

    972.73
    -3.65 (-0.37%)
     
  • GBP/EUR

    1.1046
    +0.0025 (+0.23%)
     
  • GBP/USD

    1.3063
    +0.0042 (+0.33%)
     
  • BTC-GBP

    10,406.64
    +336.03 (+3.34%)
     
  • CMC Crypto 200

    270.10
    +8.81 (+3.37%)
     
  • S&P 500

    3,397.32
    -3.65 (-0.11%)
     
  • DOW

    27,549.55
    -135.83 (-0.49%)
     
  • CRUDE OIL

    39.53
    +0.97 (+2.52%)
     
  • GOLD FUTURES

    1,909.70
    +4.00 (+0.21%)
     
  • NIKKEI 225

    23,485.80
    -8.54 (-0.04%)
     
  • HANG SENG

    24,787.19
    -131.59 (-0.53%)
     
  • DAX

    12,073.39
    -103.79 (-0.85%)
     
  • CAC 40

    4,740.31
    -75.81 (-1.57%)
     

Aladdin Healthcare Technologies will obtain an equity stake in public spinoff No-Age Biotech Inc. at TSX, aimed to combat age-related diseases

·4-min read

DGAP-News: Aladdin Healthcare Technologies SE / Key word(s): Miscellaneous/Investment
24.09.2020 / 10:50
The issuer is solely responsible for the content of this announcement.

Aladdin Healthcare Technologies will obtain an equity stake in public spinoff No-Age Biotech Inc. at TSX, aimed to combat age-related diseases
 

- Aladdin has agreed to obtain a 25% equity stake in No-Age Biotech Inc., publicly traded spinoff at TSX, in late 2020.

- No-Age Biotech will be focused on the development of therapeutics to combat age-related diseases.

- Aladdin plans to develop a bespoke drug discovery platform to be contributed to No-Age Biotech in exchange for its stake.

- No-Age Biotech will be targeting an initial valuation of $50 - $75 million or their Series A investment round.


BERLIN/LONDON, September 24, 2020 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, has agreed to obtain an equity stake in a spin-off company at the TSX (Toronto Stock Exchange) in late 2020. The spinoff has just been established and will be named No-Age Biotech Inc. The deal is subject to final terms that will be agreed in October this year. Aladdin will inform the capital market about the agreement with a further press release at an appropriate time.

Among the other founding shareholders, there are renowned and experienced professionals in the field of age-related diseases: Professor David Rubinsztein, Fellowship of the Academy of Medical Sciences and Fellow of the Royal Society, who is the Deputy Director of Cambridge Institute for Medical Research, University of Cambridge; NO-Age, a Norwegian integrated, interdisciplinary, center for human ageing research at international top level.

Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies, comments: "Aladdin plans to develop a bespoke drug discovery platform which we intend to contribute to No-Age Biotech in exchange for the 25% stake. We also expect to become the exclusive AI provider to No-Age Biotech and generate an annual fee for both development and management of the AI platform, therefore bringing significant potential value to Aladdin."

Aladdin has already achieved milestones in drug development against Alzheimer's and other age-related diseases, marking a new era for a faster and optimized identification of drug targets. In May this year, the Company announced the development of new mitophagy inducers through a novel system for virtual drug screening based on Artificial Intelligence, which is actually a key component of Aladdin's drug development platform (AIDD). This new agreement confirms again Aladdin's capability to play a relevant role in the worldwide scientific progress with its self-developed AI Drug Discovery platform AIDD and to improve the health conditions of patients with age-related and neurodegenerative diseases.

About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets age-related diseases including a significant focus on Alzheimer's disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose age-related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.

Website Link: www.aladdinid.com
GSIN: A12ULL
ISIN: DE000A12ULL2
TICKER SYMBOL: NMI

For further information:

Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone : +44 7714 719696
Email: info@aladdinid.com

Contact Press
CROSS ALLIANCE communication GmbH
Sara Pinto
Phone +49 89 1250 90330
Email: pi@crossalliance.de
www.crossalliance.de


24.09.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Aladdin Healthcare Technologies SE

Unter den Linden 10

10117 Berlin

Germany

Phone:

030 700140449

E-mail:

info@aladdinid.com

Internet:

www.aladdinid.com

ISIN:

DE000A12ULL2

WKN:

A12ULL

Listed:

Regulated Market in Dusseldorf

EQS News ID:

1136019


 

End of News

DGAP News Service

show this
show this